The Role of Extracellular Vesicles in Cancer
A special issue of Biologics (ISSN 2673-8449).
Deadline for manuscript submissions: 25 November 2024 | Viewed by 102
Special Issue Editor
Interests: extracellular vesicles; vaccine; cancer; mRNA; microRNAs; immune responses; T cells; dendritic cells; major histocompatibility complex (MHC); deep learning; virus
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Extracellular vesicles (EVs) are nanometer-sized bag-like substances released by cells. Their role is gradually being elucidated, and recently they are thought to be involved in the proliferation and metastasis of cancer cells. EVs contain various proteins, and their types as well as amounts are known to differ in lung cancer patients; however, this difference did not reflect the type or nature of the cancer cells, and it was unclear what kind of cells EVs were released from. It has long been known that sugar chains, which are sometimes referres to as the “face of a cell”, have different shapes depending on the type of cell. The shape of this sugar chain is copied almost unchanged into EVs. In cancer research, it has been revealed that they are involved in cancer metastasis, and they are attracting attention as a research subject. EVs enclose cellular proteins, DNA, mRNA, microRNA, or other nucleic acids in their small bags, and transmit information by passing them on to other cells. This Special Issue aims to highlight the latest research on the roles, molecular mechanisms, and therapeutic applications of EVs in cancers. The topics that we intend to cover include (but are not limited to) the following areas:
- EV-based therapy for cancers;
- Immune modulation of antigen presentation through EVs;
- Molecular regulation of immune responses through EVs;
- Therapeutic targets via EVs in cancers.
We invite submissions of both research and review articles and look forward to receiving your contributions.
Dr. Yasunari Matsuzaka
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- extracellular vesicle
- cancer
- immune modulation
- programmed death ligand 1
- CAR-T
